지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2020.1
- 수록면
- 728 - 735 (8page)
이용수
초록· 키워드
오류제보하기
Two major causes of steatohepatitis are alcohol and metabolic syndrome. Although the underlying causes of alcoholrelated liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) differ, there are certain similarities in terms of the mode of disease progression and underlying pathophysiological mechanisms. Further, excessive alcohol consumption is often seen in patients with metabolic syndrome, and alcoholic hepatitis exacerbation by comorbidity with metabolic syndrome is an emerging clinical problem. There are certain ethnic differences in the development of both NAFLD and ALD. Especially, Asian populations tend to be more susceptible to NAFLD, and genetic polymorphisms in patatin-like phospholipase domain-containing 3 (PNPLA3) play a key role in both NAFLD and ALD. From the viewpoint of pathophysiology, cellular stress responses, including autophagy and endoplasmic reticulum (ER) stress, are involved in the development of cellular injury in steatohepatitis. Further, gutderived bacterial products and innate immune responses in the liver most likely play a profound role in the pathogenesis of both ALD and NASH. Though the recent progress in the treatment of viral hepatitis has reduced the prevalence of viral-related development of hepatocellular carcinoma (HCC), non-viral HCC is increasing. Alcohol and metabolic syndrome synergistically exacerbate progression of steatohepatitis, resulting in carcinogenesis. The gut-liver axis is a potential therapeutic and prophylactic target for steatohepatitis and subsequent carcinogenesis.
목차
등록된 정보가 없습니다.
참고문헌 (67)
참고문헌 신청
Angulo P / 2002 / Nonalcoholic fatty liver disease / N Engl J Med 346:1221~1231
Torres DM / 2008 / Diagnosis and therapy of nonalcoholic steatohepatitis / Gastroenterology 134:1682~1698
European Association for the Study of the Liver / 2018 / EASL clinical practice guidelines : management of alcohol-related liver disease / J Hepatol 69:154~181
Crabb DW / 2020 / Diagnosis and treatment of alcohol-associated liver diseases : 2019 practice guidance from the American Association for the Study of Liver Diseases / Hepatology 71:306~333
Eckel RH / 2005 / The metabolic syndrome / Lancet 365:1415~1428
Torres DM / 2008 / Diagnosis and therapy of nonalcoholic steatohepatitis / Gastroenterology 134:1682~1698
European Association for the Study of the Liver / 2018 / EASL clinical practice guidelines : management of alcohol-related liver disease / J Hepatol 69:154~181
Crabb DW / 2020 / Diagnosis and treatment of alcohol-associated liver diseases : 2019 practice guidance from the American Association for the Study of Liver Diseases / Hepatology 71:306~333
Eckel RH / 2005 / The metabolic syndrome / Lancet 365:1415~1428
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
The Immune Landscape in Nonalcoholic Steatohepatitis
Immune Network
2016 .06
-
Recent research trends and updates on nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2019 .01
-
The effect of moderate alcohol drinking in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2020 .01
-
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
영남의대학술지
2019 .01
-
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Clinical and Molecular Hepatology
2023 .02
-
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
Journal of Yeungnam Medical Science
2019 .01
-
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
Clinical and Molecular Hepatology
2023 .04
-
Effects of Moderate Alcohol Drinking in Patients with Nonalcoholic Fatty Liver Disease
Gut and Liver
2019 .01
-
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
-
Development of non-alcoholic steatohepatitis mouse model
한국실험동물학회 학술발표대회 논문집
2021 .07
-
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Clinical and Molecular Hepatology
2023 .02
-
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2020 .01
-
Non-alcoholic fatty liver disease: Definition and subtypes
Clinical and Molecular Hepatology
2023 .02
-
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
Clinical and Molecular Hepatology
2023 .04
-
Nonalcoholic fatty liver disease and non-liver comorbidities
Clinical and Molecular Hepatology
2023 .02
-
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Clinical and Molecular Hepatology
2023 .04
-
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .04
-
Effect of Korean Red Ginseng in chronic liver disease
Journal of Ginseng Research
2017 .10
-
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Clinical and Molecular Hepatology
2023 .02
-
Non-alcoholic fatty liver disease-related hepatocellular carcinoma
Journal of Liver Cancer
2023 .03
이 논문의 저자 정보
최근 본 자료
댓글(0)
0